At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAS Phasebio Pharmaceuticals Inc
Closed 05-05 16:00:00 EDT
0.0701
+0.0000
0.00%
High0.0701Low0.0701Vol0.00
Open0.0701D1 Closing0.0701Amplitude0.00%
Mkt Cap3.50MTradable Cap2.41MTotal Shares49.86M
T/O0.00T/O Rate0.00%Tradable Shares34.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
PhaseBio announces Chapter 11 filing; plans to sell lead asset
seekingalpha  ·  2022-10-24
PhaseBio announces Chapter 11 filing; plans to sell lead asset
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
Business Wire  ·  2022-10-24
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
PhaseBio Pharmaceuticals Cut to Hold From Buy by Needham
Dow Jones  ·  2022-09-29
PhaseBio Pharmaceuticals Cut to Hold From Buy by Needham
PhaseBio Might Have To Return Global Rights To Its Lead Program
Benzinga  ·  2022-09-28
PhaseBio Might Have To Return Global Rights To Its Lead Program
PhaseBio Pharmaceuticals Cut to Market Perform From Outperform by William Blair
Dow Jones  ·  2022-09-28
PhaseBio Pharmaceuticals Cut to Market Perform From Outperform by William Blair
BRIEF-Phasebio Pharmaceuticals Says Received A Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Reuters  ·  2022-07-06
BRIEF-Phasebio Pharmaceuticals Says Received A Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
PhaseBio Pharmaceuticals: Q1 Earnings Insights
Benzinga  ·  2022-05-16
PhaseBio Pharmaceuticals: Q1 Earnings Insights
PhaseBio to seek FDA approval for clotting agent in 4Q 2022
seekingalpha  ·  2022-05-16
PhaseBio to seek FDA approval for clotting agent in 4Q 2022
PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43
seekingalpha  ·  2022-05-16
PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
Zacks  ·  2022-05-16
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
PhaseBio Pharmaceuticals Q1 EPS $(0.23) Up From $(0.87) YoY
Benzinga  ·  2022-05-16
PhaseBio Pharmaceuticals Q1 EPS $(0.23) Up From $(0.87) YoY
Phasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share
T-Reuters  ·  2022-05-16
Phasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
Business Wire  ·  2022-05-16
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
Business Wire  ·  2022-05-16
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

Introduction

Company Name.
Phasebio Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
Issue price:
--